Erythropoiesis-Stimulating Agents (ESAs): Procrit, Epogen and Aranesp: Drug Safety Communication

FDA requires REMS that ensures that only those hospitals and healthcare professionals who have enrolled and completed training in risk management program will prescribe and dispense ESAs to patients with cancer.

Related Posts:

1. Long-Acting Beta-Agonists (LABAs): New Safe Use Requirements
2. Stalevo (entacapone/carbidopa/levodopa): Ongoing Safety Review
3. Health Industry Will See More Patients With Reform; Physicians Give Mixed Reviews
4. Health Care Reform Legislation Highlights Value Of Medication Management Therapy (MTM)
5. Chantix (varenicline)